Perrigo Company plc Current State and Local Tax Expense (Benefit)
Perrigo Company plc (PRGO) reported Current State and Local Tax Expense (Benefit) of $700.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-05-22.
Discontinued › Expense Statement › Income Tax
us-gaap:CurrentStateAndLocalTaxExpenseBenefit · last filed 2017-05-22
- Perrigo Company plc current state and local tax expense (benefit) for fiscal 2016 was $700.00K.
- Perrigo Company plc current state and local tax expense (benefit) for fiscal 2015 was $6.80M, a 26.88% decline from fiscal 2014.
- Perrigo Company plc current state and local tax expense (benefit) for fiscal 2014 was $9.30M, a 13.08% decline from fiscal 2013.
- Perrigo Company plc current state and local tax expense (benefit) for fiscal 2013 was $10.70M, a 42.67% increase from fiscal 2012.
| Period end | Current State and Local Tax Expense (Benefit) 6 month | Current State and Local Tax Expense (Benefit) 6 month as first filed | Current State and Local Tax Expense (Benefit) 12 month | Current State and Local Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|
| 2016-12-31 | $700.00K 10-K · filed 2017-05-22 | |||
| 2015-12-31 | $3.00M 10-K · filed 2017-05-22 | $3.20M 10-KT · filed 2016-02-25 | ||
| 2015-06-27 | $6.80M 10-K · filed 2017-05-22 | $6.90M 10-K · filed 2015-08-13 | ||
| 2014-06-28 | $9.30M 10-K · filed 2017-05-22 | |||
| 2013-06-29 | $10.70M 10-KT · filed 2016-02-25 | |||
| 2012-06-30 | $7.50M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |